neuroendocrine tumours. The objective of this study was to develop a pharmacokinetic model for the sustainedrelease formulation lanreotide Autogel ® after deep subcutaneous administration in healthy subjects, and to explore the potential effect of covariates, especially sex and dose.
Background
meters, the design included a rapid intravenous bolus injection of an immediate-release formulation of lanreotide (lanreotide IRF).
Lanreotide is a synthetic octapeptide somatostatin analogue Study Participants and Methods used to treat acromegaly and neuroendocrine tumours; it binds preferentially to pituitary somatostatin receptors, inhibits growth
This was an open-label, single-centre, randomized, pharmacohormone secretion and reduces insulin-like growth factor I kinetic phase I study involving three parallel groups of healthy levels. [1] An earlier extended-release lanreotide formulation based subjects. The study was conducted according to the Declaration of on microparticles of lactide-glycolide copolymer allowed the reHelsinki and Good Clinical Practice guidelines. The protocol was lease of the peptide over 7-14 days after intramuscular administrareviewed and approved by the local ethics committee, and all tion. [2] The development of lanreotide Autogel ® (Somatuline participants gave their written informed consent. Autogel ® , Beaufour Ipsen, Dreux, France), a supersaturated solution containing only lanreotide and water, for subcutaneous injecParticipants tion, extended the duration of release to a more convenient dosing Inclusion of 54 healthy subjects was planned. Caucasian men interval of at least 28 days. [3] This formulation, supplied as a and women fulfilling the following criteria were included: age ready-to-use preparation (of 60, 90 or 120 mg) in pre-filled between 18 and 45 years; bodyweight within 10% of the ideal polypropylene syringes, has good effectiveness and is well toleratheight/frame; normal physical and laboratory test results; women ed in patients; the main side-effects, which are of a gastrointestinal with a negative pregnancy test who were not breastfeeding and nature, [4] [5] [6] have been similarly reported with other somatostatin who were using appropriate contraceptive methods; willingness analogues given at therapeutic doses. [7] and ability to understand and sign an approved informed consent A population model has recently been developed that relates form. lanreotide serum concentrations at steady state after administration
The exclusion criteria were a history of alcohol (ethanol) or of lanreotide microparticles or lanreotide Autogel ® with growth drug abuse; smoking of >10 cigarettes/day; history of cholehormone levels, estimating parameters associated with baseline lithiasis or gastrointestinal, renal, hepatic, pulmonary or cardiogrowth hormone levels, hormonal effectiveness and potency, as vascular disease; history of epilepsy, asthma, diabetes mellitus, well as their corresponding degree of interindividual variability psychosis or glaucoma; history of an allergic response to lanreo-(IIV). [8] The pharmacodynamic properties of lanreotide were indetide or related drugs; blood donation of ≥250 mL or participation pendent of the formulation. However, a pharmacokinetic model in a clinical trial in the 3 months before study initiation; practising relating the lanreotide serum concentration to the dose and time vegetarian diet, abnormal diet or substantial changes in eating has not been developed; so far, only descriptors such as the habits within the previous 4 weeks; treatment with any known maximum serum concentration (Cmax), minimum serum concenenzyme-inhibiting or enzyme-inducing agents in the 4 weeks tration (Cmin) and area under the serum concentration-time curve before study medication; and positive tests for HIV and/or hepati-(AUC) have been reported. [4, 9] Such a model, when combined with tis B and C. the pharmacodynamic model, could be used to explore the relationship between growth hormone levels and time in different Drug Administration and Sample Collection clinical scenarios, taking into account the IIV in both pharmacoParticipants received a single intravenous dose (7 µg/kg) of kinetic and pharmacodynamic processes. Therefore, the main oblanreotide IRF by rapid intravenous bolus injection (less than jective of the current analysis was to develop a population pharma-10 seconds), followed by 3 days of washout and then randomizacokinetic model after a single deep subcutaneous injection of tion to one of three single deep subcutaneous doses of lanreotide lanreotide Autogel ® , quantifying the degree of IIV in the pharmaAutogel ® (60, 90 or 120 mg) administered to the superior-external cokinetic parameters. Differences in the pharmacokinetic properquadrant of the buttock. Lanreotide was administered in the mornties between males and females in the case of the subcutaneous ing, and fasting conditions were not required. administration could be expected because of higher subcutaneous fat levels in women. [10] Therefore, the study of the potential effect Lanreotide IRF was obtained by reconstituting lanreotide lyof covariates of sex, in addition to the dose level, was also part of ophilisate with diluent (mannitol 40 mg/1 mL water for injections) the main objective of the analysis. To estimate the absolute bioimmediately before administration. The lanreotide Autogel ® foravailability of lanreotide Autogel ® and serum disposition paramulation consists of lanreotide acetate and water (lanreotide base, 0.246 mg/mg of solution); the hydration of the peptide leads to the difference in the MOFV of 3.84 and 6.63 points between two formation of a supersaturated solution.
nested models differing by one parameter was considered significant at the 5% and 1% levels, respectively. Since some of Blood samples for determining serum lanreotide concentrations the models that were compared were not nested, the MOFV were obtained at the following times after the intravenous bolus was not used directly for comparative purposes, and the value injection: at 0, 5, 15 and 30 minutes, then at 1, 1.5, 2, 4, 6, 8 and 12
of the Akaike Information Criteria (AIC) [14] computed as hours. After deep subcutaneous administration, samples were tak-MOFV + 2 × Np, where Np is the number of the parameters in the en for at least 6 months at 0, 1, 2, 4, 6, 8 and 12 hours during the model, was used instead. The model with the lowest value of the first day after administration and then on days 2, 3, 4, 5, 7, 14, 21, AIC, given that the precision of the model parameters and data 28, 35, 42, 49, 56, 70, 84, 98 and 112, and afterwards if necessary, description was adequate, was selected. until a serum concentration below the lower limit of quantification was reached.
Drug disposition was described with compartmental models parameterized in apparent volumes of distribution, and distribuDetermination of Serum Lanreotide Concentrations tion and elimination clearances. Different absorption models, [15] including time-dependent absorption rate constants (ka), the A previously validated radioimmunoassay (RIA) procedure Weibull model [16] and the transit compartment model, [17] were was used to determine serum lanreotide concentrations. [9] The tested to describe the absorption process after administration of lower limit of quantification was 0.078 ng/mL, and the overall lanreotide Autogel ® . precision (inter-and intra-assay), expressed as the coefficient of Demographic characteristics (age, bodyweight, sex) and the variation (CV), was 2.3-13.6% for concentrations between 0.1 and dose level were first investigated one by one for any potential 10 ng/mL. effect of covariates on all parameters associated with IIV. Significant covariates were then incorporated (starting with the covariate
Data Analysis
leading to the largest drop in the MOFV) one at a time until the full covariate model was obtained. If a covariate was added but did not All analyses were performed under the population approach cause a significant decrease in the MOFV, it was removed. This using the Laplacian numerical estimation method with interaction was followed by a backward-elimination process, whereby and the nonparametric option implemented in NONMEM ® vercovariates that were found not to be significant were dropped one sion VI software (Icon Development Solutions, Ellicott City, MD, by one until no more could be eliminated. The levels of signifi-USA). [11] cance used during the forward inclusion and backward elimination All observations were fitted simultaneously; however, in the were 5% and 1%, respectively. first step, the model describing the disposition characteristics of Model parameters were expressed as the corresponding estilanreotide in serum was developed using only the data obtained mate with the relative standard error (RSE; i.e. the ratio between after intravenous administration. Then the disposition model parathe standard error provided by NONMEM ® and the parameter meters were re-estimated when the intravenous and subcutaneous estimate). The degree of IIV was expressed as the %CV and the observations were fitted together. In the analyses, the data were additive residual variability as the standard deviation. logarithmically transformed. Approximately 10% of the observa-A predictive check was used to assess the performance of the tions at later times after administration were below the lower limit selected population model by looking at the Cmax of lanreotide and of quantification (BLQ). BLQ observations were kept in the the AUC from time zero to time of the last measurable concentradataset and were treated as censored observations (according to tion (AUClast). One thousand studies were simulated with the method 3 in Beal). [12] The method used to handle BLQ observaselected pharmacokinetic model, and for each simulated dataset, tions in the current analyses was implemented in NONMEM ® the mean Cmax and AUClast were calculated for each dose level version VI based on recent documentation. [13] IIV was modelled and sex. Then the overall mean values of the Cmax and AUClast exponentially, and residual variability was initially modelled with across the 1000 simulated studies were computed, as well as the a combined error model; if one of the components (additive or 2.5th and 97.5th percentiles, and compared with the observed proportional) of the residual error was negligible, it was deleted mean values. from the model.
Model selection was done using the minimum objective funcThe final model was further evaluated internally and externally tion value (MOFV), provided by NONMEM ® , as a guide. A using the visual predictive check method. [18] For each dose level, 1000 virtual individuals were generated on the basis of the estimates of the fixed-and random-effect parameters obtained from the selected model. The intervals including 95% of the simulated concentrations and the profile corresponding to the median were constructed and represented together with (i) the observed concentration values from the healthy subjects (internal validation) and (ii) the serum lanreotide values obtained from a phase II, multicentre, double-blind, placebo-controlled, repeated-dose, dose-ranging trial involving 105 patients with acromegaly (external validation). [19] The schedule corresponding to the fixed dose part of this phase II study consisted of three phases: determination were taken 4 weeks after the first injection and 1, 2, 3 and 4 weeks after the third or fourth lanreotide Autogel ® withdrew consent after other subjects described gastrointestinal injection. [19] AEs). Therefore, 38 subjects were randomized to receive a single subcutaneous dose of lanreotide Autogel ® . As one volunteer subsequently withdrew from the study because of a serious AE Results (described in the Safety section), 37 subjects completed the study according to the protocol. Table I lists the demographic and design
Study Participants
characteristics of the current study.
Fifty healthy subjects received a single intravenous dose of
Description of the Data lanreotide IRF. Twelve subjects withdrew after this dose but before lanreotide Autogel ® was administered (one withdrew beIndividual observed lanreotide serum concentration-time cause of adverse events [AEs; nausea, vomiting, diarrhoea and profiles for a single intravenous bolus of lanreotide IRF 7 µg/kg headache]; one because of a concurrent illness [tonsillitis]; and ten (24 women and 26 men) and for a single deep subcutaneous injection of lanreotide Autogel ® (18 women and 20 men; 60 mg, n = 13; 90 mg, n = 13; 120 mg, n = 12) are shown in figure 1.
Safety
More subjects in the lanreotide Autogel ® groups had AEs than in the lanreotide IRF group, but there were no specific dose-related trends across the lanreotide Autogel ® groups. Gastrointestinal events were the most frequent AEs in all groups (lanreotide IRF and lanreotide Autogel ® ); in particular, nausea in the lanreotide IRF group, and diarrhoea, abdominal pain, abdominal distension and vomiting in the lanreotide Autogel ® groups. One serious AE was reported, in which biliary colic occurred approximately 3 months after the single deep subcutaneous dose of lanreotide Autogel ® 60 mg and resolved after cholecystectomy. 
Pharmacokinetic Modelling
Once the disposition model for lanreotide was selected, intravenous and subcutaneous data were fitted simultaneously using a A total of 500 serum samples (109 were BLQ observations) total of 1404 serum samples (143 were BLQ observations). The from 50 subjects were used to initially select the disposition concentration-time profiles (figure 1) showed a similar pattern of pharmacokinetic model of lanreotide after rapid intravenous bolus drug release for the three dose levels of lanreotide Autogel ® and a administration. The pharmacokinetic profiles from two subjects limited initial burst effect. The Cmax occurred 7-12 hours after resembled an extravascular administration and therefore were injection. The mean Cmax values were 4.2, 8.4 and 6.8 ng/mL for treated accordingly.
Lanreotide disposition was best described by a three-compartthe 60, 90 and 120 mg doses, respectively. From day 1 to the end ment open model compared with the one-and two-compartment of the study (98, 112 and 112 days for the 60, 90 and 120 mg open models (p < 0.01). IIV was significant for total serum doses, respectively), lanreotide serum concentrations decreased clearance (CL) and the apparent volume of distribution of the gradually according to a pseudo first-order elimination profile, shallow peripheral compartment (V p1; p < 0.01). Table II lists the reflecting prolonged release of the active compound from the results from the four main models fitted to the intravenous data.
depot. Inclusion of IIV on the rest of the disposition parameters did not by NONMEM ® ; ω 2 = variance of random effects; CL = total serum clearance; F = total bioavailability; ka = first-order absorption rate constant; kb = firstorder absorption rate constant 24 h after administration; kc = first-order rate constant governing the exponential decrease in the kb as a function of ln(t); MTT = mean transit time; N = number of transit compartments; t = time after drug administration; Vc = apparent volume of distribution of the central compartment; Vp1 = apparent volume of distribution of the shallow peripheral compartment.
Models 10-13 in table II list some of the results obtained when covariates were incorporated into model 9. All of the covariates tested (bodyweight, age, sex and dose level) elicited only very marginal decreases in the MOFV with respect to model 9 (p > 0.05), and therefore none of them were incorporated into the model.
The data supported the estimation of five diagonal elements of the Ω matrix. In order to test the presence of covariance between the diagonal elements, the corresponding correlation coefficients were computed from the full Ω matrix obtained in the nonparametric step. All correlation coefficients were below 0.3, with the exception of the ones corresponding to CL versus F and k b versus kc, with values of 0.52 and 0.53, respectively. When those two off-diagonal elements were tested in NONMEM ® , both were non-significant (p > 0.05).
and first-order absorption processes, did not perform significantly Table III lists the population model parameter estimates of the better than model 6 (table II) . selected population pharmacokinetic model represented in figure  2 . All parameters were estimated with good precision and, when Three additional absorption models were also tested, and all of them fitted the data significantly better than model 6 (first-order absorption model). Model 9, where the ka was modelled as a function of time after administration, represented the best model, with a decrease in the MOFV of 27 and 269 points with respect to the Weibull model (model 7) and the transit compartment model (model 8), respectively. In model 9, the ka was modelled as an exponential decrease (to prevent the ka from being negative) using equation 1:
where kb is the value of the ka 24 hours after administration, kc is the first-order rate constant governing the exponential decrease in the kb as a function of ln(time) and t represents the time after drug administration. Model 9 provided a decrease in the MOFV of 264.7 points with respect to the model where the ka was modelled as equation 2:
The inclusion of a lag time and incomplete absolute bioavailability (F) were both significant (p < 0.01). The data supported the incorporation of IIV on F, kb and kc (p < 0.01) in addition to CL and Vp1. A different estimation of the variance in the additive residual error between the intravenous and subcutaneous data was included in the model. Figure 2 represents the model structure corresponding to model 9 in table II and shows all of the estimated parameters in the model. they were compared with those computed using the results from Autogel ® administration was 63% and showed moderate IIV the nonparametric step, the differences were negligible.
(30%). The parameter governing the decrease in the ka as a function of ln(time) was associated with a high value of IIV (96%), Figures 3 and 4 show the results of the internal visual predictive resembling the variability observed in the serum concentrationcheck, where it can be observed that the selected model is capable time profiles (figure 1). of describing the mean tendency of the data, as well as the observed variability. The plot in figure 5 representing the results of Figure 6a represents the typical profile of the k a versus time the external visual predictive check suggests that the absorption after drug administration predicted by the model. This figure and disposition properties of lanreotide Autogel ® are very similar shows that the selected model, with a relatively simple equation, between healthy subjects and acromegalic patients.
could account for the initial fast subcutaneous release, where the ka achieves the highest values during the first days of treatment, The results of the predictive check are shown in table IV, followed by prolonged release from the depot, where the ka was confirming the adequacy of the model to capture two important approximately constant from day 10 to the end of the study. data descriptors such as the Cmax and AUClast. It should be noted that in the case of intravenous administration, the dose of lanreoIn figure 6b , the typical model predicting lanreotide serum tide was adjusted by bodyweight (mean bodyweight in feconcentration-time profiles during 1 year of treatment with lanreomales = 58.8 kg; mean bodyweight in males = 74.7 kg), which tide Autogel ® administered subcutaneously once monthly at doses explains the 30% decrease in the AUC in females.
of 60, 90 and 120 mg is presented. [8] The predicted mean Cmin values at steady state (1.80, 2.70 and 3.60 ng/mL for the 60, 90 and The total value of the apparent volume of distribution, calculat-120 mg doses, respectively) were similar to those observed in ed as the sum of the apparent volumes of distribution of the patients with acromegaly at the same three dose levels (1.949, central, shallow peripheral and deep peripheral compartments, was 2.685 and 3.575 ng/mL, respectively). It should be noted that after 15.14 L, a value lower than the physiological water volume. The four once-monthly lanreotide Autogel ® injections, the fraction of estimate of CL was 23.1 L/h and its IIV was approximately 20%. The absolute bioavailability after deep subcutaneous lanreotide steady state achieved was approximately 94%. 
Discussion
parameters for extended-release formulations and justifies the design used in the current study where, during the first period, This study represents the first population pharmacokinetic analanreotide was given as an intravenous bolus. lysis of lanreotide Autogel ® in which parameters representing Disposition of lanreotide in serum could be described using a disposition in serum and absorption processes were estimated and standard three-compartment open model; however, the model for the IIV was quantified.
absorption required some elaboration. The disposition parameters of lanreotide after rapid intravenous Lanreotide acetate can form three-dimensional ordered strucbolus administration of 7 µg/kg have been characterized previoustures (liquid crystals) at high concentrations in water, and lanreoly using a noncompartmental approach in 12 healthy subjects; CL tide Autogel ® is a simple formulation comprising lanreotide acewas 17 L/h, [9] a value slightly lower than that in the current tate in water for injection at 0.246 mg of active base per milligram analysis (23.1 L/h). It is possible that such a discrepancy might of formulation. [22, 23] When lanreotide Autogel ® has been extravashave been caused by differences in the design (e.g. sampling cularly injected, the contact of the formulation with the physiologtimes, number of subjects) and the methodology of the data ical medium is thought to cause precipitation (depot formation). analysis. IIV could only be estimated in CL and Vp1 and was of Burst control and prolonged release of lanreotide Autogel ® over moderate-to-low variability. Renal elimination seems to be impor->4 weeks was achieved because of the immediate formation of this tant for lanreotide [9] and may account for the low estimate of the depot at the injection site, resulting in a slow release into the variability in CL (20%).
circulation from the depot by passive diffusion. The value of CL, together with the small apparent volume of Different absorption models were fitted to the data [15] [16] [17] and, distribution, is responsible for the rapid decline in serum lanreofinally, a modification of the standard first-order input model, tide concentrations following an intravenous bolus injection. [20] where the absorption rate decreases exponentially as a function of When lanreotide was injected as extended-release formulations, the natural logarithm of time, was selected. The inclusion of only such as micro-particles or Autogel ® , a flip-flop situation occurred. [21] This phenomenon prevents estimation of the disposition one extra parameter in the absorption model allows the description of the two sequential absorption phases: (i) the initial fast subcutafrom the depot by passive diffusion according to a slow pseudo neous release, in which the drug that had not precipitated was first-order constant rate (see figure 6a) . This model resembles the immediately absorbed into the bloodstream during the first days of physical changes occurring in the lanreotide Autogel ® formulation treatment; and (ii) the prolonged release of the active compound within the depot compartment when it has been subcutaneously injected. The limited initial burst release and controlled release over several weeks after administration at the three dose levels (60, 90 and 120 mg) demonstrated the robustness of the drug release from the formulation.
Although one might expect a difference in the bioavailability and rate of absorption due to differences in body composition between males and females at the injection site, no clinically relevant covariate effects of sex were found. A similar result was found recently after subcutaneous administration of recombinant human growth hormone. [24] The lack of involvement of bodyweight and sex in the IIV of population pharmacokinetic parameters of this model supports the use of fixed dosing and confirms the appropriateness of the deep subcutaneous route of administration for both sexes.
Our population model has been validated. Usually, because of the lack of new data, only internal validation is performed. In this study, an external validation method was also performed. The new data came from a study in which patients with acromegaly received the same doses as in the current analysis, but given in a multiple-dosing schedule (once every 4 weeks). [19] The visual inspection of figure 5 confirms that the model that was developed adequately captures the mean tendency as well as the dispersion of the data. This result indicates also that the pharmacokinetics of lanreotide Autogel ® do not differ between healthy subjects and patients with acromegaly, and that they are independent of time after the start of treatment. Figure 7 is the result of the combination of the population pharmacokinetic model selected in the present study and the population pharmacodynamic model established recently, [8] and allows an exploration of the mean and dispersion of steady-state response-time profiles. These model predictions indicate that after administration of lanreotide Autogel ® (120 mg every 28 days) at this steady state, approximately 53% of patients with acromegaly will have a controlled growth hormone level (<2.5 ng/mL) throughout the dosing interval. In addition, in the clinical study performed in patients with acromegaly, [8] it was established that a typical serum lanreotide concentration of 1.13 ng/mL reduced serum growth hormone levels to <2.5 ng/mL. Taking into account the model predictions for the Cmin at steady state (Cmin,ss), the percentage of subjects who would achieve lanreotide concentrations higher than this threshold at steady state are 69%, 86% and , showing that 81% of subjects treated with 120 mg every 56 days will have lanreotide concentrations higher than 0.48 ng/mL (the lower CI limit after 60 mg every 28 days). The mean predicted lanreotide concentration (1.14 ng/ mL) is in the same range as that found in a clinical study of patients with active acromegaly (1.6 ng/mL), in which effectiveness was demonstrated with 120 mg of lanreotide Autogel ® every 56 days. [25] In addition, 95% of subjects treated with 120 mg every 56 days will have Cmin,ss values higher than the lanreotide concentration that produced a 50% decrease in the maximum reduction in growth hormone (EC50; 0.206 ng/mL) established in a previous publication. [8] These findings provide evidence that it is feasible to extend the dosing interval for lanreotide Autogel ® 120 mg to 56 days (1.14 ng/mL) to achieve a response in the growth hormone reduction similar to that achieved after 60 mg every 28 days. The primary benefit will be a substantial reduction in the number of lanreotide Autogel ® injections required to achieve a therapeutic effect. [8] 
Conclusions
The disposition characteristics of lanreotide administered as a rapid intravenous bolus injection of 7 µg/kg were best described with a three-compartment open model. Estimates of IIV were moderate (<40%). The total apparent volume of distribution (15.1 L) was lower than the physiological water volume, and the estimate of CL was 23.1 L/h. tion for longer-term treatment, with administration at least every 4 weeks. The rate and extent of absorption of lanreotide after deep subcutaneous Autogel ® injection was not dependent on the administered dose in the range of 60-120 mg. The bioavailability was 63% of the administered dose and showed low IIV (27%). No clinically relevant relationship with any of the demographic covariates that were tested (age, bodyweight, sex, dose level) was found in the absorption and disposition properties.
The model-based simulations provide evidence that it may be clinically feasible to extend the dosing interval for lanreotide Autogel ® . A dose of 120 mg given every 56 days would achieve a similar response in growth hormone reduction to that achieved with 60 mg every 28 days. 
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